GSK, Pfizer resolve patent lawsuit over RSV vaccines
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Jakhar
Published On 2025-04-08 11:40 GMT | Update On 2025-04-08 11:40 GMT
Advertisement
Pfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing respiratory syncytial virus (RSV) vaccines, according to a filing made in Delaware federal court.
The lawsuit alleged that Pfizer’s RSV vaccine, Abrysvo, violated GSK's patent rights in its competing RSV vaccine Arexvy.
The companies said they would dismiss the case “with prejudice,” preventing it from being refiled.
Spokespeople for the companies did not immediately respond to Reuters' requests for comment and more information, including whether the case was settled.
GSK, Pfizer and Moderna have developed RSV shots approved by the U.S. Food and Drug Administration, with GSK's Arexvy responsible for the majority of U.S. RSV vaccine sales. The respiratory disease typically causes cold-like symptoms, but it is also a leading cause of pneumonia in toddlers and older adults.
GSK sued Pfizer in 2023, arguing that the New York-based company's vaccine infringed GSK patents related to antigen technology. GSK said in the lawsuit that Pfizer began working on its RSV program around 2013, at least seven years after GSK began developing its shot.
Pfizer denied the allegations and argued GSK's patents were invalid. It convinced a London court to invalidate related UK patents owned by GSK in a separate case last year.
GSK has also sued Pfizer for patent infringement in the U.S. over technology in Pfizer's blockbuster COVID-19 vaccine Comirnaty. That case is still ongoing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.